✉news HealthMedicine first seen 49 d ago, last 28 d ago, peak #16
Eli Lilly CEO pins growth hopes on weight-loss drug retatrutide
Original: Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
Eli Lilly's chief executive says the company's future has 'never been brighter' as it positions retatrutide, its experimental obesity and weight-loss medicine, as the next major growth driver. The drug would build on the momentum of Lilly's existing GLP-1 franchise, which has transformed the company's fortunes amid huge demand for obesity treatments. Investors are watching for clinical trial results and regulatory steps that will determine whether retatrutide can deliver a further boost.
Why now: Obesity drugs are one of the biggest stories in pharma, and comments from Lilly's CEO about a new pipeline candidate draw investor and market attention.
Evidence
- Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’ · stocktwits.com
API: https://socialmediatrends-api.osmike.com/v1/trends/94250